Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abcam Signs License Agreement with Pfizer

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Company to supply a range of authentic Pfizer compounds to researchers.

Abcam Plc. has announced that it has entered into a license agreement with Pfizer. Under the terms of the agreement, Abcam’s Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.

The agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research.

The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.

Steve Roome, General Manager of Abcam Biochemicals, commented: “We are delighted to have signed the license agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Acquires AxioMx
AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities.
Friday, November 13, 2015
Abcam Acquires Firefly BioWorks
Acquisition will expand Abcam’s capabilities in multiplex analysis.
Wednesday, January 21, 2015
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology.
Thursday, January 08, 2015
Abcam plc Announces Board Appointment
Appointment of Sue Harris as a non-Executive Director on the Company’s Board.
Saturday, December 13, 2014
Abcam Appoints Yvonne Chien as Chief Digital Officer
Abcam’s leadership team strengthened by new appointments.
Saturday, December 13, 2014
Abcam Wins ‘Best Use of Digital Media’ at Life Science Industry Awards
Awards recognise the world’s top performing life science suppliers.
Wednesday, November 19, 2014
Abcam Licenses Multidrug Resistance Protein 4 Inhibitors
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development.
Tuesday, September 23, 2014
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
Partnership extends Abcam’s reach within in vitro diagnostics market.
Saturday, September 06, 2014
Abcam Establishes New Direct Service for Australia and New Zealand
New service will offer researchers improved delivery times and direct technical support.
Tuesday, August 12, 2014
Abcam Announces Winner of 15 Discoveries Contest
Contest celebrates scientific breakthroughs with $15,000 research grant.
Tuesday, February 04, 2014
Abcam to Open Office in Shanghai
New office will provide dedicated support to Chinese customers.
Tuesday, January 21, 2014
Abcam Named AIM Company of the Year
The AIM awards celebrate outstanding achievement of quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months.
Monday, October 14, 2013
Abcam Appoints Alan Hirzel as Chief Marketing Officer
New role will support future growth strategies at Abcam.
Friday, June 28, 2013
Abcam Licenses Novel Technology from Columbia University for Neurobiological Research
New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.
Monday, April 08, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!